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Objectives. We assessed the safety and efficacy of stent place-
ment in patients with poorly controlled hypertension and renal
artery stenoses, which are difficult to treat with balloon angio-
plasty alone.
Background. Preliminary experience with stent placement sug-
gests improved results over balloon angioplasty alone in patients
with atherosclerotic renal artery stenosis.
Methods. Balloon-expandable stents were placed in 100 consec-
utive patients (133 renal arteries) with hypertension and renal
artery stenosis. Sixty-seven of the patients had unilateral renal
artery stenosis treated and 33 had bilateral renal artery stenoses
treated with stents placed in both renal arteries.
Results. Angiographic success, as determined by quantitative
angiography, was obtained in 132 (99%) of 133 lesions. Early
clinical success was achieved in 76% of the patients. Six months
after stent placement, the systolic blood pressure was reduced
from 173 6 25 to 147 6 23 mm Hg (p < 0.001); the diastolic
pressure from 88 6 17 to 76 6 12 mm Hg (p < 0.001); and the
mean number of antihypertensive medications per patient from
2.6 6 1 to 2.0 6 0.9 (p < 0.001). Angiographic follow-up at a mean
of 8.7 6 5.0 months in 67 patients revealed restenosis (>50%
diameter narrowing) in 15 (19%) of 80 stented vessels.
Conclusions. Renal artery stenting is an effective treatment for
renovascular hypertension, with a low angiographic restenosis
rate. Stent placement appears to be a very attractive therapy in
patients with lesions difficult to treat with balloon angioplasty
such as renal aorto-ostial lesions and restenotic lesions, as well as
after a suboptimal balloon angioplasty result.
(J Am Coll Cardiol 1997;30:1445–50)
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Percutaneous transluminal balloon angioplasty is an accepted
treatment for selected renal artery stenoses causing renovas-
cular hypertension or renal insufficiency, or both (1–6), and is
the treatment of choice for discrete lesions caused by fibro-
muscular dysplasia (2,7–10). Less satisfactory results have been
reported for atherosclerotic renovascular stenoses (3,11,12),
particularly the very proximal renal aorto-ostial stenoses (13–
17).
Results after renal artery stent placement have demon-
strated superior hemodynamic and angiographic outcomes
when compared with published results with balloon angioplasty
alone (18–21). Detailed quantitative studies involving coro-
nary artery angioplasty have documented that the major
determinant of long-term patency is early gain in lumen
diameter (22,23). If the same principle applies to the renal
arteries, it would be expected that stent placement would result
in improved patency and enhanced clinical success by achiev-
ing a greater lumen diameter than with balloon dilation alone.
The purpose of this investigation was to assess the early and
6-month results of renal artery stent placement in a consecu-
tive series of patients with poorly controlled hypertension and
renal artery stenoses that were difficult to treat with balloon
angioplasty alone.
Methods
Patient selection. The patients enrolled in this study rep-
resent a consecutive series of all patients treated with renal
artery stents from June 1992 through December 1994 at the
Ochsner Clinic (Table 1). Patients were considered candidates
for renal stent placement if they had poorly controlled hyper-
tension (systolic .150 mm Hg or diastolic .90 mm Hg or
both) while receiving medical therapy, in the presence of a
significant (.50% diameter stenosis by visual estimation on
angiography) renal artery aorto-ostial lesion or restenosis
lesion or after a suboptimal balloon angioplasty result. All
patients gave written informed consent before undergoing the
procedure.
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was defined as a serum creatinine level .1.5 mg/dl. Ostial
lesions were defined by their proximity (#1 cm) to the aorta.
Restenosis lesions were those that had recurred (.50% diam-
eter stenosis) after a previous successful balloon angioplasty
procedure, and suboptimal angioplasty results were those with
$30% residual stenosis or a large dissection after balloon
dilation.
Stent placement. Vascular access using the brachial ap-
proach was preferred when the origin of the renal artery was
cranially oriented. A 7.5F, 90-cm long vascular sheath (Daig)
with a multipurpose angiographic catheter as the introducer
was inserted through the brachial artery; 3,000 to 5,000 IU of
heparin was administered; and the target renal artery was
selectively engaged with the multipurpose introducer catheter.
Baseline angiography was performed and the lesion was
crossed with a steerable 0.035-in. (0.089-cm) guide wire. Predi-
lation of the lesion with a conventional angioplasty balloon
(4 to 8 mm in diameter and 2 cm in length) was performed to
ensure that full expansion of the lesion was possible.
The long vascular sheath was advanced across the dilated
lesion and the balloon catheter was withdrawn. A nonarticu-
lated balloon-expandable stent (Palmaz 104, 154 or 204 John-
son & Johnson Interventional Systems) was mounted on a
balloon whose nominal inflation diameter was 10% to 15%
larger than the visually estimated reference artery diameter.
The balloon-mounted stent was advanced over the guide wire
to the lesion site remaining within the shelter of the vascular
sheath. The sheath was pulled back into the aorta, uncovering
the stent at the lesion site. Contrast injections through the
vascular sheath were used to position the stent precisely. The
stent was then deployed by inflating the balloon to 6 to 8 atm.
Additional inflations with the same or larger balloons or with
higher pressures were performed or additional stents were
placed, or both, to optimize the angiographic result before final
angiography was performed.
For the femoral approach, an 8F vascular sheath was placed
percutaneously in the femoral artery, after which 3,000 to 5,000
IU of heparin was administered. An 8F renal angioplasty
guiding catheter was advanced to the renal artery and baseline
angiography was performed. The remainder of the procedure
was analogous to the brachial approach.
Medications. Patients were given 325 mg of aspirin per
day, at least 1 day before the procedure. Antihypertensive
medications were held immediately after the procedure and
the patients were observed for 18 to 24 h before resuming or
adjusting the medications. Patients were placed on warfarin for
1 to 3 months after stent placement, titrated to achieve an
international normalized ratio of 2.0 to 2.5.
Quantitative angiography. Quantitative assessment of the
angiographic images before and after stent placement was
performed using commercially available software (Image-
Comm). Quantitative measurements included the minimal
lumen diameter (MLD) of the reference segment and target
lesion, including a determination of the percent diameter
stenosis at the lesion site. The reference segment was defined
as the nearest visually normal segment of the renal artery on
angiography. Measurements were performed at baseline, after
stent placement and at follow-up.
Follow-up. Patients had blood pressure measurements and
renal function tests performed before hospital discharge and 6
months after the procedure. Follow-up angiography was
planned at 6 months after the procedure or earlier if there was
clinical suspicion of restenosis.
Outcome criteria. Angiographic success was defined as
achieving ,30% final diameter stenosis for all treated lesions
in any given patient. Clinical success was defined as normal-
ization of the blood pressure (systolic #150 mm Hg and
diastolic #90 mm Hg) while the patient received the same or
fewer medications without a major procedural complication.
Major complications included stent-related death, myocardial
infarction, bleeding requiring transfusion or vascular surgery
repair, renal failure requiring dialysis therapy, emergency renal
artery bypass surgery or stent thrombosis within 30 days of the
procedure. Angiographic restenosis was defined as .50%
diameter stenosis at the site of stent placement.
Statistical analysis. Discrete variables are presented as
percentages, and comparisons among the groups were made
with the Pearson chi-square test. Continuous variables are
expressed as the mean value 6 SD. The two-tailed, unpaired t
test was used for comparisons between the groups. Analysis of
longitudinal data was made with the two-tailed, paired t test
when the repeated measures involved two observations and
repeated measures analysis of variance for more than two
observations on the same subject. Contrast with the Bonferroni
correction was used to adjust for multiple comparisons. A p
value ,0.05 was accepted as representing statistical signifi-
cance. All calculations were performed using JMP software,
version 3.2 (SAS Institute, Inc.).
Results
Procedural results. A total of 149 balloon-expandable
stents were placed in 133 renal arteries of 100 patients, 44 of
whom also had chronic renal insufficiency (serum creatinine
.1.5 mg/dl). Stents were placed in 107 ostial lesions (80.5%),
Table 1. Clinical Characteristics of 100 Study Patients
Characteristic
Gender (M/F) 42/58
Age (yr) 67 6 10
Indication
HTN 100
CRI 44
No. of antihypertensive medications 2.6 6 1.0
Lesion location
U 62
B 33
S 5
*Data are presented as mean value 6 SD or number of patients. B 5
bilateral; CRI 5 chronic renal insufficiency (serum creatinine .1.5 mg/dl); F 5
female; HTN 5 hypertension (systolic ,150 mm Hg or diastolic .90 mm Hg, or
both, receiving medical therapy); M 5 male; S 5 solitary; U 5 unilateral.
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10 restenosis lesions (7.5%) and 16 arteries (12%) after a
suboptimal balloon angioplasty result. Thirty-three patients
with bilateral renal artery stenoses had stents placed in both
arteries, whereas 67 patients with unilateral lesions were
treated with stents, five of whom had solitary (single) kidneys.
Single stents were placed in 117 arteries (88%), and tandem
stents were placed in 16 (12%).
Angiographic results. Angiographic success was obtained
in 132 (99%) of 133 renal arteries (Fig. 1 and 2). The single
angiographic failure had a residual stenosis of 36%, as mea-
sured by quantitative angiography, which was visually under-
estimated by the operator at the time of the procedure. For all
vessels, the mean reference vessel MLD was 5.0 6 1.1 mm and
the mean lesion MLD was 1.2 6 0.6 mm, yielding an average
baseline stenosis of 75.3 6 11.1% (range 43% to 99%). After
stent placement, the lesion MLD was 4.8 6 1.0 mm and the
percent stenosis after stent placement was 1.3 6 15.7% (range
254.8% to 36.4%). The average (nominal) inflated diameter
of the balloons used to deploy the stents was 5.7 6 0.9 mm
(range 4 to 8), and the mean maximal inflation pressure was
9.4 6 2.6 atm (range 6 to 18).
Clinical outcome. Clinical success was obtained in 76% of
the patients. The baseline blood pressure was significantly
reduced before hospital discharge (Fig. 3). The average num-
ber of antihypertensive medications per patient was reduced
from 2.6 6 1 at baseline to 2.0 6 0.9 at 6 months (p , 0.001).
Renal function after stent placement showed a small de-
cline in blood urea nitrogen and no change in serum creatinine
(Fig. 4). In the 44 patients with baseline chronic renal insuffi-
ciency, the preprocedural creatinine level was 2.4 6 1.6 mg/dl
and the postprocedural creatinine level was not significantly
changed at 2.5 6 1.8 mg/dl (p 5 0.59). However, in nine
patients (22.5%) with baseline chronic renal insufficiency
(mean creatinine level of 1.8 6 0.1 mg/dl [range 1.6 to 2.0])
creatinine levels became normalized after stent placement
(1.4 6 0.1 mg/dl [range 1.2 to 1.5]) and in two patients with
normal renal function levels became slightly abnormal after
stent placement (mean creatinine 1.7 6 0.1 mg/dl).
Figure 1. Renal angiography before and af-
ter bilateral stent placement. A, Baseline
95% ostial right renal artery stenosis. B,
Baseline 80% ostial stenosis of left renal
artery. C, Final result after bilateral place-
ment of Palmaz-154 stents.
Figure 2. Angiographic and hemody-
namic results of renal stent placement.
Left panel, Baseline angiogram in top
panel with 99% eccentric lesion. Hemody-
namic gradient across the lesion is mea-
sured at 96 mm Hg. Middle panel, Unsat-
isfactory result after balloon dilation due
to lesion recoil. The angiographic residual
stenosis is .50%, and the residual hemo-
dynamic gradient is 65 mm Hg. Right
panel, Final result after placement of a
Palmaz-154 stent deployed with a 6.0-mm
balloon. Note minimal residual stenosis
on angiography and no residual hemody-
namic gradient across the stent. AO 5
aorta; PTCA 5 percutaneous translumi-
nal coronary angioplasty; RA 5 right
atrium.
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Complications. One major complication, subacute stent
thrombosis, occurred 3 days after stent placement in this series
of patients. Two patients experienced transient contrast ne-
phropathy without need for dialysis. There were no guide wire
perforations or emergency renal artery bypass procedures.
There were seven access-site complications, including groin
hematomas in five patients, one femoral artery pseudoaneu-
rysm that resolved with external compression using duplex
ultrasound guidance and one brachial artery occlusion that
occurred after sheath removal and was resolved with balloon
dilation from a femoral access site. One patient had a sudden
ischemic cardiac death 2 days after hospital discharge, which
was determined to be unrelated to the stent placement.
Procedural difficulties encountered and subsequently re-
solved included failure to deploy a stent on the initial attempt
in two patients. In one patient, the balloon developed a leak
and the stent could not be deployed. The partially expanded
stent was withdrawn on the balloon, and a second stent was
successfully placed. In another patient an undeployed stent
became embolized from the balloon catheter but remained on
the guide wire at the level of the common iliac artery. The stent
was retrieved through the vascular sheath with a loop snare,
and a second stent was successfully deployed in the renal
artery.
Late complications (.30 days from stent placement to
6-month follow-up) included non–stent-related death in two
patients. One patient died of complications of heart failure 2
months after stent placement, and one patient died of compli-
cations of a myocardial infarction 4 months after stent place-
ment.
Follow-up. Six months after stent placement, the mean
systolic blood pressure was reduced from 173 6 25 to 146 6
20 mm Hg (p , 0.01) and the mean diastolic pressure from
88 6 17 to 77 6 12 mm Hg (p , 0.01) (Fig. 3). Angiographic
follow-up at a mean of 8.7 6 5.0 months in 67 patients revealed
restenosis (.50% diameter narrowing) in 15 (18.8%) of 80
stented vessels. At the follow-up visit, patients with angio-
graphic restenosis tended to have a higher systolic blood
pressure (155 6 15 vs. 145 6 21 mm Hg [p 5 0.09]) than those
without restenosis, but there was almost no difference in
diastolic blood pressure (75 6 14 vs. 77 6 12 mm Hg [p 5
0.78]).
Quantitative angiographic measurements revealed signifi-
cant differences in the immediate post-stent MLD for patent
vessels (4.9 6 0.9 mm) compared with restenotic lesions (4.3 6
0.7 mm) (p 5 0.025) and in the late loss (post-stent MLD
minus follow-up MLD) for restenosis vessels (3.0 6 1.4 mm)
compared with patent vessels (1.3 6 0.9 mm) (p , 0.001)
(Table 2).
Discussion
This series of consecutive patients demonstrates the safety
and efficacy of renal stent placement for lesions considered
difficult to treat with balloon angioplasty. Our technical success
in 99% of lesions, clinical success in 76% of patients and only
one major stent-related complication compare very favorably
with published results of balloon angioplasty for renal artery
stenosis (1–6) and are consistent with previous published
reports for renal artery stent placement (18–21).
Figure 3. Line chart showing systolic (top) and diastolic (bottom)
blood pressure response after stent placement (mean 6 SD). *p , 0.01
compared with baseline. DBP 5 diastolic blood pressure; SBP 5
systolic blood pressure.
Figure 4. Bar graph of renal function before and after stent placement
(mean 6 SD). BUN 5 blood urea nitrogen.
Table 2. Follow-Up Angiographic Results for 80 Renal Arteries in
67 Patients
Characteristic
Restenosis
(n 5 15)
Patent
(n 5 65) p Value
Stent MLD (mm) 4.3 6 0.7 4.9 6 0.9 0.025
Late loss (mm) 3.0 6 1.4 1.3 6 0.9 ,0.001
Acute gain (mm) 3.2 6 0.8 3.6 6 0.9 0.114
Nominal balloon size (mm) 5.7 6 0.9 5.8 6 0.9 0.844
Maximal inflation (atm) 9.5 6 1.7 9.1 6 2.8 0.659
Reference MLD (mm) 4.6 6 1.2 5.1 6 1.1 0.120
Lesion MLD (mm) 1.2 6 0.5 1.3 6 0.6 0.325
No. of stents 1.2 6 0.4 1.1 6 0.3 0.336
Data are presented as mean value 6 SD. MLD 5 minimal lumen diameter.
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The 6-month outcomes in our patients demonstrated sus-
tained benefit with regard to lower blood pressure and fewer
antihypertensive medications required. An angiographic re-
stenosis rate of 18.8%, in the two-thirds of patients undergoing
follow-up angiography, is encouraging considering the diffi-
culty in convincing asymptomatic patients to undergo repeat
angiography, which may have resulted in a bias favoring
angiographic follow-up in patients with clinical evidence of
restenosis.
Our 6-month angiographic restenosis rate is comparable to
the 16% to 25% restenosis rate in previous studies (18,20) and
is significantly better than the 39% restenosis rate in a com-
parable group of 28 patients treated with renal stents in a
multicenter study by Rees et al. (21). There may be several
reasons for this discrepancy in the latter study, including 1)
their use of 20-mm long, articulated stents (stents with 1-mm
gaps in their center) versus our use of nonarticulated stents,
95% of which were #15 mm; and 2) their underdeployment of
stents as they attempted to match the reference artery size,
whereas we used slightly oversized stents with regard to the
reference artery diameter.
The benefit of endolumen stent placement comes from the
stent’s ability to scaffold the endolumen surface of the dilated
lesion and to resist the inherent elastic recoil of the dilated
artery to maximize the lumen area. The ability of the stent to
overcome the elastic recoil of the stented vessel is an advan-
tage over balloon dilation alone, and results in a larger early
gain in the MLD.
We attempted to use slightly oversized stents compared
with the reference vessel diameter. The nominal size of the
balloon used to deploy the stents (5.7 6 0.9 mm) was larger
than that of the quantitatively measured reference vessel
(5.0 6 1.1 mm, p , 0.001). However, the final lumen diameter
after stent placement (4.8 6 1.0 mm) was slightly smaller than
the reference vessel diameter. This reflects incomplete expan-
sion of the stent at the balloon inflation pressures used for
deployment (9.4 6 2.6 atm).
The only procedural variable that was related to angio-
graphic restenosis in our patients was the post-stent MLD.
There was no difference among patients with or without
restenosis regarding the nominal balloon diameter or maximal
inflation pressure used for stent deployment. Therefore, safely
achieving the lowest residual stenosis after stent deployment by
employing higher inflation pressures or larger balloons to more
fully expand a suboptimally dilated stent should be the goal
when placing renal stents.
For the total group of patients, there was a slight improve-
ment in blood urea nitrogen but no significant change in serum
creatinine after stent placement, nor was there a significant
difference in the baseline or follow-up serum creatinine levels
for the groups with or without renal insufficiency. It is note-
worthy, however, that nine patients (22.5%) with mild baseline
renal insufficiency did not have normalized renal function after
the stent procedure.
Study limitations. The limitations of this investigation are
that it was not a randomized study, so no direct comparison
with balloon angioplasty is possible; and that follow-up angiog-
raphy was not performed in all patients. However, at the time
of this study, we were unwilling to randomize this group of
patients because we believed balloon angioplasty alone was an
unattractive choice for treatment of this subset of renal artery
lesions.
Indications for stent placement. These data suggest that
elective stent placement is the procedure of choice for patients
with difficult lesions for balloon angioplasty alone. Determin-
ing the benefit of primary stent placement for other renal
artery lesions currently adequately treated with balloon angio-
plasty will require a randomized trial.
The issue of preserving or improving renal function with
percutaneous renal artery revascularization is an important
one. The natural history of renal artery stenosis is progressive
in nature (24–26). Given the low restenosis rate obtained in
our study, renal stent placement may prevent progressive renal
artery stenosis and subsequent loss of renal function. Previous
reports of renal angioplasty as well as stent placement have
documented improvement in renal function in some patients
with renal failure, but this has not been predictable (4,5,12,18–
21). A separate issue is whether treating more moderate
stenoses of the renal arteries (50% to 70% diameter stenosis)
in patients with normal renal function and without hyperten-
sion will prevent loss of renal function in the long term. This
will require a prospective, randomized study.
Conclusions. We have demonstrated excellent angio-
graphic and clinical results of stent placement for renal artery
stenosis in a consecutive series of patients with poorly con-
trolled hypertension and lesions difficult to treat with balloon
angioplasty alone. To obtain the best results every effort should
be made to optimize stent expansion and minimize residual
vessel stenosis. Stent placement appears to be a very attractive
therapy for renovascular hypertension in patients with lesions
difficult to treat with balloon angioplasty alone, such as ostial
lesions and restenotic lesions, as well as after a suboptimal
angiographic result after balloon dilation alone.
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